Business Insights
  • Home
  • Crypto
  • Finance Expert
  • Business
  • Invest News
  • Investing
  • Trading
  • Forex
  • Videos
  • Economy
  • Tech
  • Contact

Archives

  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • August 2023
  • January 2023
  • December 2021
  • July 2021
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019

Categories

  • Business
  • Crypto
  • Economy
  • Finance Expert
  • Forex
  • Invest News
  • Investing
  • Tech
  • Trading
  • Uncategorized
  • Videos
Apply Loan
Money Visa
Advertise Us
Money Visa
  • Home
  • Crypto
  • Finance Expert
  • Business
  • Invest News
  • Investing
  • Trading
  • Forex
  • Videos
  • Economy
  • Tech
  • Contact
PagSeguro Digital Ltd. (PAGS) Stock Drops Despite Market Gains: Important Facts to Note
  • Investing

Why Sensus Healthcare, Inc. (SRTS) Outpaced the Stock Market Today

  • July 17, 2025
  • Roubens Andy King
Total
0
Shares
0
0
0
Total
0
Shares
Share 0
Tweet 0
Pin it 0

In the latest close session, Sensus Healthcare, Inc. (SRTS) was up +2.54% at $4.44. The stock's change was more than the S&P 500's daily gain of 0.54%. Meanwhile, the Dow experienced a rise of 0.52%, and the technology-dominated Nasdaq saw an increase of 0.74%.

Prior to today's trading, shares of the company had lost 8.65% lagged the Medical sector's loss of 2.12% and the S&P 500's gain of 4.2%.

The investment community will be closely monitoring the performance of Sensus Healthcare, Inc. in its forthcoming earnings report. The company is predicted to post an EPS of $0.01, indicating a 90% decline compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.8 million, down 4.76% from the year-ago period.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.11 per share and a revenue of $41.95 million, indicating changes of -73.17% and +0.34%, respectively, from the former year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Sensus Healthcare, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Sensus Healthcare, Inc. is currently sporting a Zacks Rank of #4 (Sell).

Investors should also note Sensus Healthcare, Inc.'s current valuation metrics, including its Forward P/E ratio of 39.36. This indicates a premium in contrast to its industry's Forward P/E of 22.47.

The Medical – Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 35% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Roubens Andy King

Previous Article
Lululemon just made a risky move most retailers avoid
  • Trading

Lululemon just made a risky move most retailers avoid

  • July 17, 2025
  • Roubens Andy King
Read More
Next Article
Syfe Portfolio Performance Review H1 2025: Dollar Down, Diversification Up
  • Invest News

Syfe Portfolio Performance Review H1 2025: Dollar Down, Diversification Up

  • July 17, 2025
  • Roubens Andy King
Read More
You May Also Like
Read More
  • Investing

The most popular stocks and funds investors bought in August

  • Roubens Andy King
  • September 10, 2025
Apple, Oracle, Novo Nordisk, Inditex and Vistry
Read More
  • Investing

Apple, Oracle, Novo Nordisk, Inditex and Vistry

  • Roubens Andy King
  • September 10, 2025
Morningstar PitchBook index tracks exposure to public and private assets
Read More
  • Investing

Morningstar PitchBook index tracks exposure to public and private assets

  • Roubens Andy King
  • September 10, 2025
Oil prices rise on Middle East tensions and Trump’s tariff push
Read More
  • Investing

Oil prices rise on Middle East tensions and Trump’s tariff push

  • Roubens Andy King
  • September 10, 2025
Lennar (LEN) Stock Dips While Market Gains: Key Facts
Read More
  • Investing

Lennar (LEN) Stock Dips While Market Gains: Key Facts

  • Roubens Andy King
  • September 10, 2025
Zoetis (ZTS) Stock Sinks As Market Gains: Here’s Why
Read More
  • Investing

Zoetis (ZTS) Stock Sinks As Market Gains: Here’s Why

  • Roubens Andy King
  • September 10, 2025
Crescent Energy (CRGY) Stock Drops Despite Market Gains: Important Facts to Note
Read More
  • Investing

Crescent Energy (CRGY) Stock Drops Despite Market Gains: Important Facts to Note

  • Roubens Andy King
  • September 10, 2025
Asia stocks gain, bonds fall as traders consider odds of bigger Fed cut
Read More
  • Investing

Asia stocks gain, bonds fall as traders consider odds of bigger Fed cut

  • Roubens Andy King
  • September 9, 2025

Recent Posts

  • The most popular stocks and funds investors bought in August
  • Analysts Flag Key Signals Ahead Of Inflation Data
  • How to Turn Crypto News into Trade Signals Using Grok 4
  • Apple, Oracle, Novo Nordisk, Inditex and Vistry
  • Bitcoin Has Not Yet Hit Seller ‘Exhaustion’
Featured Posts
  • The most popular stocks and funds investors bought in August
    • September 10, 2025
  • Analysts Flag Key Signals Ahead Of Inflation Data 2
    Analysts Flag Key Signals Ahead Of Inflation Data
    • September 10, 2025
  • How to Turn Crypto News into Trade Signals Using Grok 4 3
    How to Turn Crypto News into Trade Signals Using Grok 4
    • September 10, 2025
  • Apple, Oracle, Novo Nordisk, Inditex and Vistry 4
    Apple, Oracle, Novo Nordisk, Inditex and Vistry
    • September 10, 2025
  • Bitcoin Has Not Yet Hit Seller ‘Exhaustion’ 5
    Bitcoin Has Not Yet Hit Seller ‘Exhaustion’
    • September 10, 2025
Recent Posts
  • Georgia Secures 0M Partnership to Advance Tokenized Real‑World Asset (RWA) Agriculture
    Georgia Secures $100M Partnership to Advance Tokenized Real‑World Asset (RWA) Agriculture
    • September 10, 2025
  • Morningstar PitchBook index tracks exposure to public and private assets
    Morningstar PitchBook index tracks exposure to public and private assets
    • September 10, 2025
  • Sygnum Integrates Bybit Into Bank-Grade off‑exchange Custody Network
    Sygnum Integrates Bybit Into Bank-Grade off‑exchange Custody Network
    • September 10, 2025
Categories
  • Business (2,057)
  • Crypto (1,619)
  • Economy (123)
  • Finance Expert (1,687)
  • Forex (1,618)
  • Invest News (2,361)
  • Investing (1,541)
  • Tech (2,056)
  • Trading (2,024)
  • Uncategorized (2)
  • Videos (814)

Subscribe

Subscribe now to our newsletter

Money Visa
  • Privacy Policy
  • DMCA
  • Terms of Use
Money & Invest Advices

Input your search keywords and press Enter.